Nephrotic syndrome is defined by heavy proteinuria, hypoalbuminemia, edema and hyperlipidemia. Podocin (NPHS2) is an integral membrane protein of podocytes in the glomerular filtration barrier. The aim of this study was to verify if different variants, previously identified in the promoter region of NPHS2 gene in non-related SRNS patients, affect podocin expression.
Introduction
Nephrotic syndrome (NS), one of the most common kidney diseases in childhood, is characterized by massive proteinuria, hypoalbuminemia, edema and hyperlipidemia. Approximately 20% of the patients do not respond well to corticosteroid treatment and are classified as steroidresistant NS (SRNS) 1 . NPHS2 gene encodes for podocin that is an integral membrane protein of podocytes in the glomerular filtration barrier (Figure 1 ). Variants in the NPHS2 gene are responsible for approximately 40% and 16% of familial and sporadic SRNS cases, respectively 2 . 
Results and Discussion
The variants c.-164C>T and c.-268C>G showed -49,1% and -66,6% downregulation of luciferase (Renilla sp) gene expression, respectively, when compared to the wild-type NPHS2 promoter, when transfected in podocytes (Figure 3) . Our results corroborate with previous results from Di Duca et al (2006) 3 study in which they also found that other promoter variants downregulated podocin. 
Conclusions
Our results indicate that changes in podocin expression might interfere in the glomerular filtration slit and act in the background of the NS in patients carrying those variations. Luciferase activity expressed in podocytes
